Furthermore, regorafenib, one of the main second-line drugs administered when sorafenib fails, demonstrated for the first time that its anti-tumor action in sorafenib-refractory HCC is mediated, at least in part, through FOXO3 downregulation and autophagy abolition. Here, FOXO3 is linked to hepatocellular carcinoma.